OneMedNet Stock Slumps 27% as It Files for 39.65M Share Offering

Introduction

ONEMEDNET CORP (Nasdaq: ONMD) is a public company headquartered in Eden Prairie, Minnesota, specializing in real-world data (RWD) solutions for healthcare and other industries. Founded in 2006, the company’s proprietary iRWD™ platform provides de-identified, longitudinal patient records—clinical exams, imaging data, and administrative claims—across more than 1,750 provider sites. OneMedNet’s subscription-based model supports drug manufacturers, device companies, and AI developers seeking regulatory-grade datasets without personally identifiable information.

Corporate Structure

OneMedNet employs between 11 and 50 staff members, including executives and a board of directors with dedicated committees for audit, compensation, and governance. Key leadership includes:

• Aaron Green, President and Chief Executive Officer, overseeing strategy and network expansion.
• Dr. Jeffrey Yu, Vice President and Chief Medical Officer, a board-certified radiologist involved in the company's founding imaging technology.
• Bob Golden, Chief Financial Officer, a certified public accountant with over 30 years of experience in middle-market finance.
• Steven Chartier, Vice President of Engineering and Chief of Data, responsible for product development and data architecture.

Real-world data by Luke Chesser

Developments and News

On August 4, 2025, OneMedNet reported second-quarter results showing access to 136 million clinical exams and a network of 1,750 sites. The company submitted its Form 10-Q for Q2 and a prospectus supplement (Rule 424(b)(3)) dated August 13, 2025, outlining a primary offering of up to 11.5 million common shares and a secondary offering of up to 28.15 million shares to satisfy registration rights and support working capital. In June 2025, OneMedNet announced strategic agreements to expand imaging-data access, and on July 31, 2025, it detailed collaborations focused on clinical application development.

Financial and Strategic Analysis

On August 15, 2025, ONMD closed at $0.70, down 26.97% from the prior session, with a volume of 544,315 shares. The stock’s 52-week range is $0.30 to $1.56. As of mid-August, market capitalization stands at approximately $44 million and enterprise value at $28.8 million. Trailing twelve-month revenue is approximately $532,000 against a net loss of $9.9 million, yielding an EPS of –$0.34 and a price-to-sales ratio of 27.4. Total cash on the balance sheet is $144,000, and the company has issued $1.66 million in convertible notes, positioning it for potential capital infusions.

Strategically, OneMedNet employs AI-driven data-masking technology and quality controls to deliver compliant, production-ready datasets. Its subscription model supports operational scalability, and the longitudinal nature of its platform, particularly in medical imaging, differentiates it within the RWD market.

Market Position and Industry Context

The global market for real-world evidence is driven by demand for post-market surveillance, AI training, and regulatory submissions. OneMedNet competes with other RWD providers by offering a platform that integrates electronic health records, claims, and imaging data. Its network of over 1,750 healthcare sites and focus on regulatory-grade datasets aim to address the need for large-scale, de-identified data while complying with HIPAA and other privacy standards.

tl;dr

On August 4, 2025, OneMedNet’s Q2 report highlighted access to 136 million clinical exams and 1,750 provider sites on its iRWD™ network. On August 13, 2025, the company filed its Form 10-Q and a prospectus to offer up to 39.65 million shares, supporting working capital needs. As of August 15, the shares closed at $0.70, down 26.97%, with a market cap of approximately $44 million and TTM revenue of $532,000. Upcoming catalysts include warrant exercises, further network growth, and expanded data-licensing agreements.